OncoBEAM™ BRAF (RUO) kit

  • Detection of BRAF V600E mutation
  • Highly sensitive BEAMing digital PCR technology
  • A more rapid and minimally invasive assessment of BRAF mutation, as compared to tissue biopsy
  • Catalog Number ZR150050

Detection of cell-free tumor DNA in metastatic colorectal cancer patients through a simple blood draw – The OncoBEAM™ BRAF Kit (RUO)*

The OncoBEAM™ BRAF Kit is a Research Use Only (RUO) assay for the qualitative detection of BRAF V600E mutation in cell-free DNA extracted from plasma using BEAMing digital PCR technology that employs beads-based amplification in water-in-oil emulsions and allele-specific hybridization followed by flow cytometry.

*for research use only, not for diagnostic use

RAS Mutation Frequency in Colorectal Cancer

RAS Mutation Frequency in Colorectal Cancer

Clinical significance of BRAF V600E mutations and RAS/BRAF somatic mutation frequency in colorectal cancer

  • A BRAF V600E mutation is an indicator of poor prognosis for metastatic colorectal cancer patients (mCRC). 1
  • Clinical practice guidelines recommend BRAF mutation analysis in all patients with mCRC at diegnosis of stage IV disease. 2,4
  • The potential clinical utility of BRAF inhibitors in combination with anti-EGFR therapy is currently being investigated in clinical trials. 5,6,7
  • Monitoring of KRAS/NRAS/BRAF mutations in plasma using BEAMing may provide early insight into predicting clinical outcomes in mCRC patients. 8
The OncoBEAM™ Advantages

The OncoBEAM™ Advantages

Safety and Convenience
Minimally invasive, few risks

Accurate Information
Blood sample evaluation represents current mutational status of patient's disease; Information of tumor dynamics in real time

No Selection Bias
Evaluate primary tumor and metastases with one sample

Ability to Monitor
Allows multiple measurements to assess drug response and resistance

Time Sensitive
Rapid turnaround time from biopsy to result

 

 

References

References

1. Van Cutsem E et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29(15): 2011-2019.
2. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer Version 2 2017.
3. Van Cutsem E et al. ESMO consensus guidelines for management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27(8): 1386-1422.
4. Sepulveda AR et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Oncol Pract 2017; 13(5): 333-337.
5. Hong DS et al. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 2016; 6(12): 1352-1365
6. Yaeger R et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res 2015; 21(6): 1313-1320.
7. Tabenero J et al. Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). ASCO Annual Meeting 2016; Abstract 3544.
8. Toledo RA et al. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget 2017; 8(21): 35289-35300.

Contact

Sales Support

info@sysmex-inostics.com

Create Pdf